Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well darolutamide and leuprolide acetate works in treating
androgen receptor positive salivary cancer that has spread from where it started to other
places in the body (metastatic), that cannot be removed by surgery (unresectable) or that has
come back (after a period of improvement) (recurrent). Darolutamide is in a class of
medications called androgen receptor inhibitors. It works by blocking the effects of androgen
(a male reproductive hormone) to stop the growth and spread of cancer cells. Leuprolide
acetate injection is in a class of medications called gonadotropin-releasing hormone
agonists. It works by decreasing the amount of certain hormones in the body. Giving
darolutamide in combination with leuprolide acetate may help to stop the growth of tumor
cells that need androgens to grow.